EyeYon Medical
Tel Aviv, Israel· Est.
Israeli biotech delivering sustained‑release ocular implants for retinal disease therapy.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $30M
AI Company Overview
Israeli biotech delivering sustained‑release ocular implants for retinal disease therapy.
OphthalmologyRetinal diseases
Technology Platform
A proprietary biodegradable polymer implant that provides sustained, controlled release of therapeutic agents to the back of the eye.
Opportunities
Expansion of the platform to multiple retinal indications and potential licensing deals with large pharma for biologic payloads.
Risk Factors
Regulatory approval uncertainty, competition from established ocular drug delivery systems, and challenges in scaling implant manufacturing.
Competitive Landscape
Competes with Ozurdex, Ocular Therapeutix, and emerging gene‑therapy approaches; differentiation stems from platform flexibility and ability to deliver both small molecules and biologics.